ADPT
Adaptive Biotechnologies Corp
NASDAQ: ADPT · HEALTHCARE · BIOTECHNOLOGY
$13.53
-3.63% today
Updated 2026-04-29
Market cap
$2.16B
P/E ratio
—
P/S ratio
7.80x
EPS (TTM)
$-0.39
Dividend yield
—
52W range
$8 – $21
Volume
1.9M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
7.3
Growth
B+5.5
Quality
C+2.0
Profitability
F6.7
Valuation
B5/9
Piotroski F-Score
Moderate
-2.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$20.57
+52.03%
12-Month target
—
—
Intrinsic (DCF)
$32.68
Margin of safety
+52.20%
2 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $1.42M — positive
+ Revenue growth 51.00% QoQ
+ 52.20% below intrinsic value
Risks
- Altman Z -2.53 — distress zone
- Thin margins at -21.50%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $185.31M | $170.28M | $178.96M | $276.98M | $276.98M |
| Net income | $-200.19M | $-225.25M | $-159.49M | $-59.50M | $-13.58M |
| EPS | — | — | — | — | $-0.39 |
| Free cash flow | $-200.29M | $-167.02M | $-98.88M | $-48.95M | $1.42M |
| Profit margin | -108.03% | -132.29% | -89.12% | -21.48% | -21.50% |
Peer comparison
Smart narrative
Adaptive Biotechnologies Corp trades at $13.53. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -2.53, it sits in the distress. TTM revenue stands at $276.98M. with profit margins at -21.50%. Our DCF model estimates intrinsic value at $32.68.
Frequently asked questions
What is Adaptive Biotechnologies Corp's stock price?
Adaptive Biotechnologies Corp (ADPT) trades at $13.53.
Is Adaptive Biotechnologies Corp overvalued?
Smart Value Score 32/100 (Grade F, Strong Sell). DCF value $32.68.
What is the price target of Adaptive Biotechnologies Corp (ADPT)?
The analyst target price is $20.57, representing +52.0% upside from the current price of $13.53.
What is the intrinsic value of Adaptive Biotechnologies Corp (ADPT)?
Based on our DCF model, intrinsic value is $32.68, a +52.2% margin of safety versus $13.53.
What is Adaptive Biotechnologies Corp's revenue?
TTM revenue is $276.98M.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
-2.53 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio7.80x
ROE-27.80%
Beta2.30
50D MA$14.41
200D MA$14.87
Shares out0.16B
Float0.12B
Short ratio—
Avg volume1.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—